The US FDA commissioner revealed that the agency has requested the manufacturers of rosiglitazone (Avandia) and pioglitazone (Actos) to add black-box warnings about the risk for heart failure with these drugs.
The FDA indicated that the request was made because although the drugs currently carry warnings about potential heart failure, they are still sometimes being prescribed to patients with this condition thus creating a need for stricter action.
Reference: New York Times dated 7th June 2007
http://www.nytimes.com/2007/06/07/health/07drug.html?_r=1&hp=&adxnnl=1&oref=slogin&adxnnlx=1181219366-DOm2snpHxZbSZJFCCGfiqw
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment